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Abstract
Cancer remains the second major cause of death in the world. Thus, there is a
pressing need to identify potential synthetic route for the development of novel
anticancer agents which will serve as lead compounds to eﬀectively combat this
life-threatening epidemic. Pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) have
sparked a great interest as lead compounds because of their cancerostatic and
anti-infective properties. The twisted molecular structure of PBD analogs
provides both helical and chiral elements. In an eﬀort to expand novel PBDs that
interact with the key exocyclic amino group of the DNA-guanine base, we
hypothesized that construction of a fused cyclic active system, would likely serve
as an electrophilic site when compared to traditional electrophilic C11-N10 imine
group. To examine our theory, we report herein the synthesis and cell viability/
cytotoxicity of a series of PBD analogs using NCI-60 cell lines screening. Thus,
compounds 1e13 were synthesized and fully characterized. The selected PBDs
were found to have marginal inhibition of growth, up to 30%, for certain cell lines.
Keywords: Organic chemistry, Pharmaceutical chemistry
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1. Introduction
Naturally occurring pyrrolobenzodiazepines (PBDs) were ﬁrst discovered in the cell
cultures of the Streptomyces species in the 1960s [1]. The ﬁrst PBD molecule to be
separated and characterized was anthramycin [2]. Since then, a number of naturally
occurring PBDs have been isolated from the Streptomyces sp. which include sibiromycin and tomaymycin, among others [3, 4]. It is presumed that the PBD molecules were evolved by the Streptomyces species as a form of chemical defense;
however, scientists have made use of their antibiotic properties for the treatment
of cancer.
To date, thirteen natural PBD structures have been isolated from the Streptomyces
species (Fig. 1) [5]. Of the thirteen PBD products that have been isolated, both anthramycin and sibiromycin were shown to have broad spectrum anti-tumor activity invitro and as a result, they have been tested clinically. Anthramycin particularly was
found to have signiﬁcant cytotoxicity against gastrointestinal, breast cancers, lymphomas and sarcomas without having signiﬁcantly side eﬀects towards red blood
cells; however, due to its cardiotoxicity, anthramycin’s clinical use was limited [6, 7].
Pyrrolobenzodiazepines are deﬁned by their tricyclic structure, which is composed
of an aromatic A-ring, a 1,4-diazepin-5-one B-ring, and a pyrrolidine C-ring. The
PBD compounds diﬀer from one another by the location and type of substituent
groups on all three rings. The C-11a carbon has an S-conﬁguration, which gives
the molecules a right-handed twist. In addition to their right handed-twist, it is
important to note that the natural PBDs can exist in three interchangeable forms at
their N10-C11 position: imine, carbinolamine, and carbinolamine methyl ether
[8]. The choice of solvent most certainly has an eﬀect on which form exists in solution. However, the three interconvertible forms are normally considered to be equivalent. In all cases, the C11 position of the PBDs is electrophilic [9, 10].
O
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PBDs have an S-conﬁguration at carbon C11a which gives the molecules a righthanded twist. This right-handed twist allows the PBDs to ﬁt snugly within the
DNA double helix, enabling them to interact with the minor groove. In fact, a synthetic PBD with R-conﬁguration at C11a was shown to lack DNA binding aﬃnity
and in vitro cytotoxicity. In combination with the right-handed twist of the molecules, electrophilic carbon atom at the C11 position allows the PBDs to alkylate
the nucleophilic NH2 group of the guanine in the minor groove of DNA. Several
studies have shown that the reaction between PBDs and DNA is sequence selective,
preferentially targeting 50 -purine-G-purine sequences [11, 12]. The covalent bonds
that the PBDs form to the amino group of the guanine base allows the molecules
to act as an adduct that blocks biological processes such as transcription and RNA
polymerase progression. The cytotoxic/antitumor activities of PBDs are attributed
to these reactions.
Due to the eﬀorts to synthesize PBDs which shared the characteristics of the relatively successful natural PBD products, a dimer by the name of SJG-136 was synthesized and was shown to be signiﬁcantly cytotoxic in vitro. As a result of
impressive in vitro studies, SJG136 was tested thoroughly in vivo against 10 human
tumor xenografts, including but not limited to melanomas, ovarian carcinomas,
breast cancer, colon cancer, and lung cancer. Due to the impressive and extensive
data collected regarding SJG136’s activity in pre-clinical trials, the compound
entered clinical Phase I testing against advanced solid tumors in 2004. SJG-136,
is presently in phase II clinical trials for treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer. Furthermore, in the past decade there has
been a growing interest in PBD dilactams where their N10-C11 amidic moiety have
shown a tolerable robustness towards a number of synthetic transformations of the
amide functionality to the DNA-alkylating imine as well as 5- and 6-membered
fused heterocycles. Additionally, PBD dilactams and their tetracyclic analogs
have presented interesting biological activity towards several diﬀerent targets.
In continuation to our previous attempts to discover novel bioactive PBDs and
improvement of their eﬃcacy [13, 14, 15, 16], we became interested in the synthesis
and characterization of a new class of tetracyclic PBD derivatives with fused heterocyclic moiety. We evaluated a panel of thirteen novel PBD’s for in vitro cytotoxicity
using NCI-60 cell lines screening.

2. Results and discussion
2.1. Chemistry
The synthesis of all PBD derivatives were accomplished with the readily available
basic structure of PBD natural product (1) (from Isatis indigotica [17]) used as
the starting material.
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As depicted in the synthesis plan (Fig. 2), the cyclocondensation of equimolar
mixture of L-proline and isatoic anhydride in DMF at 155  C [18, 19] by a standard
protocol aﬀorded dilactam 1 which was recrystallized from a 10:1 v/v mixture of
acetone and DMF to obtain compound 1 as oﬀ white crystals. Thionation of compound 1 with 0.5 equiv Lawesson’s reagent in THF at room temperature aﬀorded
thiolactam 2 [13, 20].
Catalytic amination of thiolactam 2 using n-propylamine in the presence of mercuric(II)chloride as catalyst aﬀorded compound 3 after being recrystallized from nitromethane. In the solid state, compound 3 exists as the exocyclic imine in the Z
conﬁguration, as evidenced by a single crystal X-ray analysis of a N-phenylimino
analog [21]. The bond length of the C]N bond was determined to be shorter the
N(10)eC(11) distance. The cyclization of compound 3 with bis (2,4,6trichlorophenyl)-2-phenylmalonate at 190  C using a zincke apparatus was performed under neat conditions to yield the pyrimidine-annulated PBD 4. Cyclization
reactions of N,N0 -disubstituted amidines with bis-(2,4,6-trichlorophenyl)-2phenylmalonates have generally been shown to result in the formation of pyridinium-4-olates. The loss of two molecules of trichlorophenol through a ketene intermediate during ring closure is thought to be one of the possible mechanistic
explanations for the syntheses of these compounds [20, 21].
A standard protocol was followed for the treatment of 2 with hydrazine monohydrate
in ethanol at room temperature to aﬀord compound 7 in a quantitative yield which
was further used as the main precursor for the syntheses of triazole-3-one 8 and

Fig. 2. Reagents and conditions: (a) DMF, 155  C, 5h, 82.0%; (b) Lawesson’s reagent, THF, rt, 15h,
87.0%; (c) n-propylamine, HgCl2, rx, 1h, 88%; (d) bis(2,4,6-trichlorophenyl)-2-phenylmalonate,
190  C, 10 min, 75%; (e) NH3(g)(anhy.), HgCl2, THF, rx, 1h, 86% (f) bis(2,4,6-trichlorophenyl)-2phenylmalonate, 170e180  C, 10 min, 63%; (g) N2H4.H2O (98%), EtOH(abs.), rt, 15h, 99.0%; (h)
CDI, dioxane (anhy.), reﬂux, 24h, 99.0%; (i) TDI, dioxane (anhy.), rx, 24h, 80.0%; (j) NH2OH.HCl,
K2CO3, ethanol, rt, 24h, 82%; (k) CDI, dioxane, rx, 12h, 88%/TDI, dioxane, rx, 12h, 90%; (l) a-bromoacetyl chloride, THF, rt, under N2(g), 15h, 75%. CDI: 1,10 -carbonyldiimidazole, TDI: 1,10 thiocarbonyldiimidazole.
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mercapto-triazole 9 PBDs [22]. Carbonylation of 7 with 1,10 -carbonyldiimidazole
(CDI) in dioxane under reﬂux resulted in the formation of 8. Upon further puriﬁcation by ﬂash chromatography on silica gel column, pure 8 was formed as white crystals. Likewise, treatment of 7 with thiocarbonyldiimidazole (TDI) in dioxane under
reﬂux produced 9. Puriﬁcation of crude product was performed on a silica gel column chromatography to yield pure 9 as yellow solid. Recrystallization from methanol aﬀorded yellow single crystals in 80% overall yield. In contrast to the
carbonylation of 7, inspection of spectral data clearly revealed that thionylation of
the substrate with TDI generated an aromatic triazole ring system with a thiol substitution (9) instead of a thionyl compound [22]. This observation is dedicated to the
low electronegativity and larger atomic size of sulphur which consequently leads to
the construction of an aromatic tautomer.
The synthetic procedure for compound 10 was optimized with some modiﬁcation to
the protocol previously reported by Rekowski et al. and Bartsch et al. Treatment of
compound 2 with hydroxylamine hydrochloride under basic conditions led to the
formation of 10, which in turn was puriﬁed by recrystallization from nitromethane
to give pure 10 as yellow needle-like crystals [23, 24]. Our experience showed
that the use of K2CO3 as a relatively milder base rather than reported trimethylamine,
signiﬁcantly increased the reaction yield up to 94%. A possible explanation for this
observation could be the ability of the K2CO3 to eﬀectively neutralize the HCl and
the gradual accessibility of hydroxylamine to attack by the electrophilic thionyl carbon in 2.
Compound 10 was further used as the main precursor for the synthesis of oxadiazole-3-one 11 and oxadiazole-3-thione 12 by respective carbonylation and thiocarbonylation reactions [23, 24]. A slight modiﬁcation was made to the reported
protocol to develop more eﬃcient syntheses of 11 and 12. Treatment of 10 with
CDI and TDI under reﬂux in anhydrous dioxane for 12 hours aﬀorded 11 and 12
in 88% and 90% yield, respectively. According to the literature, both reactions in
THF under reﬂux for 24 hours produce their respective products in 84% yields.

3. Biological activity
3.1. In vitro cytotoxicity
To determine whether our PBD compounds were cytotoxic towards cancer cells,
nine PBD analogs were selected for the single-dose in vitro cytotoxicity using a
panel of NCI-60 cell lines as part of Developmental Therapeutics Program (DTP)
at the National Cancer Institute (Table 1). Compounds that selected for the NCI60 cell screening were tested at a single concentration of 10 mM. All the compounds
showed some non-selective growth inhibition on T-47D breast cell line ranging from
6.7 to 12.7%. Interestingly, PBDs 3 and 4 were displayed their highest inhibition on
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Table 1. In vitro cytotoxicity data of PBD derivatives against various NCI-60 cell lines.
Cancer

Cell line

PBD Compounds-Growth Percent
3

4

5

6

8

10

11

12

13

HL-60(TB)
SR

101.38
102.79

103.22
103.91

103.05
95.32

101.26
103.31

101.25
92.26

90.92
99.34

103
103.8

94.58
91.96

87.83
101.39

NSCL

HOP-62
NCI-H522

101.62
84.29

89.44
77.82

84.60
83.64

90.25
78.63

77.32
76.35

91.39
79.92

80.34
90.49

92.91
76.82

87.54
81.50

Colon

HCT-116
HT29

100.33
97.57

96.01
99.46

96.12
101.60

99.44
95.26

98.34
98.65

98.34
94.64

101.09
95.04

95.49
99.63

88.64
91.31

CNS

SNB-75
U251

77.68
98.25

87.15
99.23

83.05
91.64

84.45
98.40

88.78
95.70

93.52
96.42

89.29
96.22

90.43
95.79

85.08
96.22

Melanoma

SKMEL-2
MALME-3M

95.73
92.15

91.26
95.68

96.42
97.19

96.80
94.85

90.48
88.95

91.71
95.21

97.71
83.85

82.08
98.70

94.75
100.22

Ovarian

NCI/ADR-RES
SK-OV-3

97.24
103.74

95.76
98.55

102.94
95.20

95.62
106.55

104.82
88.06

100.80
101.62

99.31
88.46

104.39
92.95

100.73
90.84

Renal

UO-31
TK-10

85.88
92.55

83.90
94.15

78.66
94.62

71.55
90.33

89.20
96.45

86.24
92.33

88.38
95.19

87.04
96.05

80.50
98.39

Prostate

PC-3

98.28

95.79

89.08

90.37

95.76

95.37

97.71

90.70

88.45

Breast

T-47D
HS 578T

88.30
94.34

88.54
98.16

89.48
92.43

91.74
94.98

83.60
96.69

92.91
99.98

93.26
98.31

91.42
96.79

87.23
94.58
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SNB-75 (CNS) (22.3%) and NCI-H522 (NSCL) (22.2%), respectively. Growth of
the NCI-H522 cell line was inhibited by all the PBDs ranging from 9.5% to
23.7%. All nine PBDs inhibited growth on the renal cell line, UO-31, ranging
from 10.8% to 28.5%. Overall the best inhibition activity was exhibited by PBD 6
which acts on the renal UO-31 cell line with 28.5% growth inhibition.

3.2. MTT cell viability test
To further examine our preliminary cytotoxicity results from NCI-60 cell lines in
higher concentrations, the MTT in house assay was used for the selected cell lines.
Similar results were obtained in agreement with the NCI-60 cell lines (Fig. 3). The
PBD compounds were dosed at 100 mM, and allowed to incubate for 48 hours. Based
on the previously reported works, the preferred cell lines that were used for the MTT
assay were breast (SK-BR-3, MCF-7), colon (CaCo-2, HCT 116), melanoma
(SKMEL-2), and pancreatic (Mia Paca) cell lines. Unlike other biological activity
assays, we did not have access to the reference compound (positive control) for
in vitro cytotoxicity/cell viability tests. Basically we cannot use the commercially
available anti-cancer drugs because they possess a diﬀerent target than BPD derived
compounds. The only available potent antitumor agents are natural products such as
anthramycin, tomaymycin, and sibiromycin which are either very expensive to purchase or too complicated to synthesize.
The results show that nearly all of the novel PBD compounds, except for compound 13,
reduced the cell viability of MCF-7 cells by roughly up to 27% (Fig. 3). In contrast,
virtually none of the PBD analogs, with the exception of compounds 1 and 10, had
an anti-proliferative eﬀect on the SKMEL-2 cell line. Additionally, all compounds
that were tested on HCT-116 and Mia Paca showed no cytotoxic eﬀects. The PBD 1
showed a decrease in cell viability for the SKBR-3, MCF-7, SKMEL-2, and CaCo 2
cell lines; however, the PBD dilactam showed no cytotoxicity towards HCT 116 or
Mia Paca. The greatest amount of cytotoxicity for compound 1 was a reduction of
cell viability by 20.3% and 20.1% for both MCF-7 and SKMEL-2 cell lines,
160
SKBR-3 (Breast)

Cell Viability (% of control)

140

MCF-7 (Breast)

120

SKMEL-2 (Melanoma)

100

CaCo 2 (Colon)

80

HCT 116 (Colon)
Mia Paca (Pancreac)

60
40
20
0

1

2

3

4

5

6

8

10

11

PBD Compounds

Fig. 3. In vitro cytotoxicity assay of PBD analogs from MTT Assay.
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respectively. PBD 2 showed a clear reduction of cell viability for MCF-7 and CaCo 2,
while having the greatest amount of anti-proliferative eﬀects on the MCF-7 cell line
(17.7%). However, PBD 2 did not noticeably decrease the cell viability of cell lines
SKBR-3, SKMEL-2, HCT 116, or Mia Paca. PBD 3 had a relatively low eﬀect on
the cell viabilities of MCF-7 (10.4%) and CaCo 2 (7.5%) cells, while had no negative
eﬀect on the cell growth of SKBR-3, Mia Paca, SKMEL 2, and HCT 116 cell lines.
PBD 4 had a noticeable eﬀect on the cell viabilities of SKBR-3 (17.3%) and MCF-7
(22.5%). However, PBD 4 had no negative eﬀects on the cell growth of SKMEL-2,
CaCo 2, HCT 116, or Mia Paca cell lines. PBD 5 showed the highest growth inhibition
against MCF-7 cell line (26.4%) when compared with other tested analogs. PBD 5 had
no negative aﬀect on the cell viability of SKBR-3, SKMEL-2, and CaCo 2. PBDs 6 and
8 displayed some reduction in the cell viability of SKMEL-2 with values of 19.9% and
17.0%, respectively. PBDs 10 and 11 showed their highest inhibition activity versus
SKMEL-2 breast cell line with 13.0% and 10.5%, respectively. PBD 13 had a selective
anti-proliferative eﬀect on CaCo 2 cell line (13.6%).

4. Conclusion
To synthesize PBDs 1e13 with side chain functionality at C11-N10 imino group, we
either employed a new approach or developed a shorter and more eﬃcient syntheses
than those previously reported. The novel synthetic PBD’s evaluated in this study
demonstrated a range of biological activities similar to what has been described
for the various naturally occurring PBDs. Among these activities, we saw a promising speciﬁcity when assaying the cytotoxic activity of nine of the synthesized
PBDs where all showed some inhibition of growth on the renal cell line UO-31
with PBD 6 showing the greatest eﬃcacy. PBD 8 also showed inhibition of growth
in both the HOP-62 and NCI-H522 cell lines. Additional investigation of the cell
viability/cytotoxicity of these compounds, as well as development of derivatives
of the studied PBDs, is in progress.

5. Experimental
General Experimental Procedures. All reactions proceeded from the commercially available L-proline and isatoic anhydride. Unless otherwise stated, all reagents
and solvents were obtained from commercial vendors and utilized without further
puriﬁcation. 1H NMR, 13C NMR, GC-MS and IR spectroscopy were the techniques
used for the characterization of the synthesized compounds. JEOL-NMR Eclipse400 MHz spectrophotometer provided all NMR data and spectra. The high frequency position conversion gave the diﬀerent chemical shifts of all peaks in parts
per million (ppm) with the coupling constants value (J) reported in Hz. The splitting
patterns of resonance were also described as follows: singlet (s), doublet (d), doublet
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of doublet (dd), doublet of doublet of doublet (ddd), triplet (t), quartet (q), and multiplet (m). Genesis II FT-IR spectrometer was also used for all IR spectra. Cambridge
Melt-Temp device provided melting point readings but without correction for the
synthesized compounds. Shimadzu GC-MS 2010 System provided the relative
abundances of the smaller ion fragments from the molecular ion of all compounds.
Other common chromatographic techniques such as thin layer chromatography and
column chromatography were also employed in the puriﬁcation of all synthesized
compounds. Compounds 5 and 6 were synthesized according to previously reported
methods [15].
(S)-1,2,3,11a-tetrahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]

diazepine-5,11(10H)-

dione (1). Dilactam (1) was synthesized according to the previously reported
methods with some modiﬁcations [17]. A suspension of isotaic anhydride (10.0 g,
61.34 mmol) and L-proline (7.06 g, 61.34 mmol) in N,N-dimethylformamide
(DMF) (50 mL) was heated to 155  C for 5 h. After cooling to room temperature,
the solvent was removed in vacuo and the residue was taken up in water. The precipitate was collected and dried to give an oﬀ-white solid. Recrystallization from
Acetone/DMF (10:1 v/v) aﬀorded 10.87 g (82%) of pure compound 1 as oﬀ-white
1

crystals. Yield: 82.0%; m.p: 223e225  C; [a]25
D ¼ þ512 (c 0.5, MeOH); HNMR (400 MHz, DMSO-d6): d ¼ 1.80 (d, J ¼ 9.9 Hz, 1H), 1.85e2.07 (m, 2H),
3.39e3.52 (m, 1H), 3.51e3.67 (m, 1H), 4.02e4.21 (m, 1H), 7.07e7.17 (m, 1H),
7.17e7.27 (m, 1H), 7.51 (ddd, J ¼ 8.6, 6.8, 1.3 Hz, 1H), 7.78 (dd, J ¼ 7.9, 1.6
Hz, 1H), 10.52 (s, 1H); 13C-NMR (100 MHz, DMSO-d6): d ¼ 23.6 (C-2), 26.3
(C-1), 47.4 (C-3), 56.8 (C-11a), 121.8, 124.4, 127.1, 130.8, 132.6, 136.9, 165.0
~ (cm1) ¼ 3222 (N-H), 3206, 2955, 2918, 2850,
(CO), 171.3 (CO); IR (KBr) n
1691 (C]O), 1680 (C]O), 1621, 1551, 1536, 1479, 1443, 1412, 1385, 1285,
1259, 1179, 759, 701, 615; GC-MS (70 eV) m/z (%): 216 (10) [Mþ], 119 (14),
92 (20), 70 (100), 64 (10); HRMS m/z calcd for C12H13N2O2 [MþH]þ 217.0977,
found 217.0982.
(S)-11-thioxo-1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo [1,2-a][1,4]diazepin-5-one (2). A mixture of compound 1 (21.60 g, 100 mmol) and Lawesson’s reagent (20.2 g, 50 mmol) in THF (400 mL) was stirred over night at room
temperature. Evaporation of solvent in vacuo gave a crude solid yellow residue.
The solid was washed with toluene and further washed with cold toluene to aﬀord
20.2 g (87%) of pure compound 2 as yellow solid [17]. Yield: 87.0%; m.p:
1

272e274  C; [a]25
D ¼ þ762 (c 0.5, CHCl3); H-NMR (400 MHz, DMSO-d6):
d ¼ 1.83e1.98 (m, 1H), 1.98e2.15 (m, 2H), 2.88 (d, J ¼ 5.9 Hz, 1H),
3.31e3.51 (m, 3H), 3.53e3.60 (m, 1H), 4.28 (d, J ¼ 6.2 Hz, 1H), 7.29 (d, J ¼
8.1 Hz, 1H), 7.32e7.39 (m, 1H), 7.58 (td, J ¼ 7.7, 1.2 Hz, 1H), 7.83 (dd, J ¼
7.7, 1.5 Hz, 1H); 13C-NMR (100 MHz, DMSO-d6): d ¼ 23.2 (C-2), 29.5 (C-1),
47.4 (C-3), 60.3 (C-11a), 122.3, 126.2, 128.3, 130.8, 132.7, 137.0, 164.7 (CO),
~ (cm1) ¼ 3125 (N-H), 3094, 3063, 3024, 2974, 1620
202.5 (CS); IR (KBr) n
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(C]O), 1579, 1523, 1478, 1452, 1418, 1381, 1272, 1193, 1166, 1145, 1103, 1069,
1055, 887, 833, 817, 786, 755, 695, 664, 625; GC-MS (70 eV) m/z (%): 232 (7)
[Mþ], 108 (6), 70 (100), 68 (6); HRMS m/z calcd for C12H13N2OS [MþH]þ
233.0749, found 233.0737.
(S,Z)-11-(propylimino)-1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo[1,2-a]
[1,4]diazepin-5-one (3). To a stirred suspension of compound 2 (5.80 g, 25.0 mmol)
and propylamine (20 mL) was added HgCl2 (7.14 g, 26.25 mmol) at 60  C. The
mixture was stirred for further 1 h at this temperature. After cooling to room temperature, the mixture was ﬁltered through a plug of celite and eluted with dichloromethane (CH2Cl2) [13]. The ﬁltrate was washed with saturated Na2S2O3 and after
extraction with CH2Cl2, the combined organic layers were dried over magnesium
sulfate (MgSO4), ﬁltered, and the solvent and excess amine were evaporated under
reduced pressure. The crude solid was puriﬁed by recrystallization in nitromethane
to aﬀord 5.64 g of pure compound 3 as colorless crystals. Yield: 88.0%; m.p:
1

159e161  C; [a]25
D ¼ þ1106 (c 0.5, CHCl3); H-NMR (400 MHz, CDCl3): d ¼
0.98 (t, J ¼ 7.5 Hz, 3H), 1.48e1.72 (m, 2H), 2.03 (q, J ¼ 8.9 Hz, 1H), 2.12 (d, J
¼ 7.0 Hz, 1H), 2.18e2.29 (m, 2H), 3.38 (d, J ¼ 4.8 Hz, 2H), 3.50e3.64 (m,
1H), 3.82e3.93 (m, 1H), 4.03 (t, J ¼ 4.9 Hz, 1H), 4.69 (s, 1H), 7.02e7.13 (m,
2H), 7.38 (ddd, J ¼ 8.6, 6.8, 1.3 Hz, 1H), 7.92 (dd, J ¼ 7.7, 1.5 Hz, 1H); 13CNMR (100 MHz, CDCl3): d ¼ 11.7 (CH3), 22.3 (CH2), 23.9 (CH2), 26.8 (C-2),
43.3 (C-1), 46.5 (C-3), 54.4 (C-11a), 122.2, 126.5, 126.9, 130.1, 131.6, 146.7,
~ (cm1) ¼ 3851, 3798, 3745, 3356 (N-H),
156.2 (C-N), 166.8 (CO); IR (KBr) n
3319 (N-H), 3287, 3061, 2941, 2880, 2815, 2359, 2328, 1826, 1791, 1731, 1605
(C]O), 1554, 1531, 1506, 1456, 1406, 1383, 1336, 1256, 1215, 1150, 1096,
1067, 1035, 991, 918, 835, 761, 703, 635; GC-MS (70 eV) m/z (%): 257 (21)
[Mþ], 146 (23), 119 (23), 90 (21), 70 (100); HRMS m/z calcd for C15H20N3O
[MþH]þ 258.1606, found 258.1629.
3-Phenyl-1-propyl-1,12,13,14,14a,14b-hexahydro-2H,10H-benzo[e]pyrimido[2,1c]pyrrolo[1,2-a][1,4]diazepine-2,4,10(3H)-trione (4). A mixture of 3 (1 mmol,
0.257 g) and bis(2,4,6-trichloro phenyl)-2-phenylmalonate (1 mmol, 0.539 g) was
heated at 190  C for 10 minutes in a Zincke apparatus under high vacuum. The residue was treated with diethyl ether to give a dark brown precipitate which was
collected by ﬁltration and washed with diethyl ether. Recrystallization was done

in 2-propanol. Yield: 300 mg (75%) m.p.: 230e233  C; [a]25
D ¼ 0 (c ¼ 0.5,
1
CHCl3); H-NMR (400 MHz, CDCl3): d ¼ 0.77e0.81 (t, J ¼ 7.3 Hz, 3H),

1.31e1.39 (m, 2H), 2.04e2.17 (m, 1H), 2.21e2.28 (m, 1H), 2.62e2.71 (m, 1H),
2.77e2.82 (dd, J ¼ 14.6, 6.2 Hz, 1H), 2.96e3.03 (m, 1H), 3.96e4.11 (m, 2H),
4.17e4.25 (m, 1H), 4.71 (s, 1H), 7.28e7.30 (m, 2H), 7.36e7.45 (m, 5H),
7.54e7.59 (td, J ¼ 7.8, 1.6 Hz, 1H), 8.02e8.04 (m, 1H); 13C-NMR (100 MHz,
CDCl3): d ¼ 11.2, 20.6, 21.5, 29.6, 48.4, 49.5, 59.1, 118.0, 125.5, 127.5, 128.2,
~
128.4, 130.8, 131.3, 132.3, 133.3 (CO), 139.8 (CO), 167 (CO); IR (KBr): n
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(cm1) ¼ 2957, 2918, 2860, 2355, 1958, 1728, 1683 (C]O), 1633 (C]O), 1576,
1487, 1453, 1352, 1297, 1252, 1221, 1185, 1150, 899, 800, 753, 719, 698, 665, 631;
UV lmax (AcO): 194, 274 nm; GC-MS (70 eV) m/z (%): 401 (66) [Mþ], 215 (11),
187 (29), 118 (100), 90 (46); HRMS m/z calcd for C24H23N3O3 [MþH]þ 402.1812,
found 402.1801.
(S,E)-11-amino-1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one (5). To a stirred suspension of monothiolactam 2 (1.16 g, 5.0 mmol) in anhydrous THF (50 mL) was added HgCl2 (1.63 g, 6.0 mmol) and pure anhydrous ammonia
was bubbled through the mixture for 1 h at 60  C. After cooling, the resulting suspension was ﬁltered oﬀ through a pad of Celite and eluted with methanol. The solvent was
evaporated under reduced pressure. The resultant solid was puriﬁed by recrystallization from anisole/methanol to aﬀord pure colorless crystals [14]. Yield: 0.925 g
1

(86%); m.p.: >235  C (dec.); [a]25
D ¼ þ515 (c ¼ 0.5 in MeOH); H-NMR (400
MHz, DMSO-d6): d ¼ 1.93e2.04 (m, 2H), 2.10e2.19 (m, 1H), 2.43e2.59 (m, 1H),
3.35e3.42 (m, 1H), 3.63e3.69 (m, 1H), 4.25 (d, J ¼ 7.8 Hz, 1H), 7.15 (d, J ¼ 7.5
Hz, 1H), 7.24 (t, J ¼ 7.5 Hz, 1H), 7.30e7.72 (br s, 2H, NH2), 7.51e7.56 (m, 1H),
7.81 (dd, J ¼ 7.8, 1.5 Hz, 1H); 13C-NMR (100 MHz, DMSO-d6): d ¼ 24.0 (C-2),
26.7 (C-1), 47.4 (C-3), 55.1 (C-11a), 124.6, 125.1, 127.7, 131.0, 132.8, 141.3,
~ (cm1) ¼ 3356 (N-H), 3125 (NH), 1614
164.3 (C-N), 165.4 (CO); IR (KBr): n
(C]O), 1578, 1456, 1239; GC-MS (70 eV) m/z (%): 215 (39) [Mþ], 70 (100);
HRMS m/z calcd for C12H14N3O [MþH]þ 216.1137, found 216.1139.
(S)-3-phenyl-1,12,13,14,14a,14b-hexahydro-2H,10H-benzo[e]pyrimido[2,1-c]pyrrolo[1,2-a][1,4]diazepine-2,4,10(3H)-trione (6). A mixture of 5 (1 mmol, 0.215 g)
and bis(2,4,6-trichlorophenyl) 2-phenylmalonate (1 mmol, 0.539 g) was heated at
170e180  C for 10 minutes in a Zincke apparatus under high vacuum. The residue
was treated with diethyl ether to give a dark brown precipitate which was collected
by ﬁltration and washed with diethyl ether. Recrystallization was performed in

DMF/Water. Yield: 228 mg (63 %); m.p.: >250  C (dec.); [a]25
D ¼ 34 (c ¼ 0.5

in MeOH); 1H-NMR (400 MHz, DMSO-d6): d ¼ 1.92e1.97 (m, 1H), 2.01e2.14
(m, 2H), 2.75e2.77 (m, 1H), 3.37e3.44 (m, 1H), 3.58e3.69 (m, 1H), 4.50 (d, J
¼ 6.3 Hz, 1H), 7.12e7.15 (m, 1H), 7.21e7.27 (m, 4H), 7.48 (d, J ¼ 8.0 Hz,
1H), 7.52e7.55 (m, 1H), 7.59e7.64 (m, 1H), 7.80 (dd, J ¼ 7. 5, 1.1 Hz, 1H),
11.71 (s, 1H).

13

C-NMR (100 MHz, CDCl3): d ¼ 24.1 (C-2), 27.0 (C-1), 47.0 (C-

3), 58.9 (C-11a), 101.6, 126.6, 129.0, 129.2, 129.3, 129.7, 129.8, 131.1, 132.6,
~ (cm1) ¼ 1667,
133.8, 141.4, 158.0, 163.8, 164.2, 164.5 (C]O); IR (KBr): n
1626, 1604, 1558, 1458; GC-MS (70 eV) m/z (%): 359 (100) [Mþ]; HRMS m/z
calcd for C21H18N3O3 [MþH]þ 360.1348, found 360.1365.
(S,E)-11-hydrazono-1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]
diazepin-5-one (7). To a solution of compound 2 (1.16 g, 5.0 mmol) in ethanol (20
mL) was added 98% hydrazine monohydrate (0.75 g, 15.0 mmol) and stirred for 15 h
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at room temperature. The solvent was removed in vacuo and the residue was taken
up in water. The precipitate was collected, dried and washed with diethyl ether to
aﬀord 1.14 g (99%) of compound 7 as oﬀ-white solid [15]. Yield: 99.0%; m.p:
1

178e180  C; [a]25
D ¼ þ552 (c 0.5, MeOH); H-NMR (400 MHz, CDCl3): d ¼
1.61e2.08 (m, 4H), 2.65e2.82 (m, 1H), 3.57e3.69 (m, 1H), 3.71e3.84 (m, 1H),
4.17e4.30 (m, 1H), 6.85 (d, J ¼ 8.1 Hz, 1H), 7.09 (t, J ¼ 7.7 Hz, 1H),
7.32e7.40 (m, 1H), 7.90 (dd, J ¼ 7.9, 1.3 Hz, 1H); 13C-NMR (100 MHz,
CDCl3): d ¼ 23.4 (C-2), 26.1 (C-1), 47.3 (C-3), 55.5 (C-11a), 119.7, 123.0,
125.4, 131.5, 132.5, 137.8, 152.2, 166.2 (CO); IR (KBr): 3484, 3282, 3240,
3161, 2967, 2949, 2871, 2814, 2422, 2358, 2336, 1957, 1854, 1784, 1766, 1726,
1689, 1658, 1619, 1563, 1539, 1529, 1479, 1442, 1384, 1323, 1272, 1202, 1076,
943, 903, 825; HRMS m/z calcd for C12H15N4O [MþH]þ 231.1246, found
231.1239.
(S)-11,12,13,13a-tetrahydro-9H-benzo[e]pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]
diazepine-3,9(2H)-dione (8). A solution of compound 7 (0.69 g, 3.0 mmol) and 1,10 carbonyldiimidazole (3.89 g, 24.0 mmol) in dioxane (25 mL) was reﬂuxed for 24 h.
The solvent was removed in vacuo and the crude product was puriﬁed by ﬂash gel
column chromatography using gradient elution. The ratios of solvent mixture used
were EtOAc/Hexane (1:1, 2:1, 4:1 v/v) and a ﬁnal elution with only Ethyl acetate
(EtOAc). Recrystallization from EtOAc/Hexane (4:1 v/v) aﬀorded 0.76 g (99%)
of pure compound 8 as white crystals. Yield: 99.0%; m.p: 238e240  C; [a]25
D ¼
þ136 (c ¼ 0.5, DMSO); 1H-NMR (400 MHz, CDCl3): d ¼ 1.99e2.22 (m, 2H),
2.23e2.37 (m, 1H), 2.86 (ddd, J ¼ 16.3, 6.8, 3.7 Hz, 1H), 3.64e3.75 (m, 1H),
3.81e3.92 (m, 1H), 4.53 (dd, J ¼ 8.4, 3.3 Hz, 1H), 7.42e7.51 (m, 1H),
7.59e7.67 (m, 1H), 7.90e7.98 (m, 1H), 8.03 (dd, J ¼ 7.9, 1.6 Hz, 1H), 9.90 (s,
1H);

13

C-NMR (100 MHz, CDCl3): d ¼ 23.5 (C-2), 26.0 (C-1), 47.7 (C-3), 51.7

(C-11a), 123.0, 127.8, 129.0, 130.1, 131.9, 132.3, 153.9 (CO), 164.7 (CO); IR
(KBr): 3435, 3375, 3183, 3091, 3000, 2909, 2878, 2814, 2326, 1711, 1611, 1574,
1490, 1466, 1412, 1343, 1285, 1239, 1202, 1167, 1118, 1072, 1024, 979, 926,
912, 825, 786, 758, 709, 656, 616; GC-MS (70 eV) m/z (%): 256 (60) [Mþ], 102
(26), 90 (38), 43 (100); HRMS m/z calcd for C13H12N4O2 [MþH]þ 257.1033, found
257.1012.
(S)-3-mercapto-11,12,13,13a-tetrahydro-9H-benzo[e]pyrrolo[1,2-a][1,2,4]triazolo
[3,4-c][1,4]diazepin-9-one (9). A solution of compound 7 (0.23 g, 1.0 mmol) and
1,10 -thiocarbonyldiimidazole (1.42 g, 8.0 mmol) in dioxane (20 mL) was reﬂuxed
for 24 h. The solvent was removed in vacuo and the crude product was puriﬁed
by ﬂash gel column chromatography using gradient elution. The ratios of solvent
mixture used were Acetone/Hexane (10:1, 20:1 v/v). Recrystallization from
EtOAc/Hexane (4:1 v/v) aﬀorded 0.217 g (80%) of pure compound 9 as brown crys1

tals. Yield: 80.0%; m.p: >230  C (dec.); [a]25
D ¼ þ37.5 (c 0.4, CHCl3); H-NMR
(400 MHz, CDCl3): d ¼ 1.62e1.99 (m, 1H), 2.03e2.28 (m, 2H), 2.29e2.45 (m,
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1H), 2.89 (tt, J ¼ 9.9, 3.4 Hz, 1H), 3.63e3.78 (m, 1H), 3.81e3.97 (m, 1H), 4.55 (dd,
J ¼ 8.4, 2.9 Hz, 1H), 7.50e7.60 (m, 1H), 7.63e7.77 (m, 1H), 8.04 (dd, J ¼ 7.7, 1.5
Hz, 1H), 8.39 (d, J ¼ 8.1 Hz, 1H); 13C-NMR (100 MHz, DMSO-d6): d ¼ 23.6 (C-2),
26.7 (C-1), 47.5 (C-3), 51.6 (C-11a), 126.2, 129.1, 130.6, 130.8, 131.2, 131.4,
~ (cm1) ¼ 3735, 3280, 3174, 3127,
153.1, 164.0 (CO), 167.7 (CS); IR (KBr) n
3096, 3060, 2989, 2944, 2880, 2827, 2415, 2359, 2331, 1958, 1760, 1723, 1686,
1611, 1542, 1488, 1410, 1344, 1310, 1286, 1216, 1112, 1043, 1003, 973, 921,
892, 876, 825, 756, 704, 664, 638, 622, 610; GC-MS (70 eV) m/z (%): 272 (100)
[Mþ], 116 (23), 90 (34), 70 (33); HRMS m/z calcd for C13H12N4O1S [MþH]þ
273.0805, found 273.0833.
(S,E)-11-(hydroxyimino)-1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo[1,2-a]
[1,4]diazepin-5-one (10). To a solution of compound 2 (1.16 g, 5.0 mmol) in ethanol
(30 mL) was added the hydroxylamine hydrochloride (0.417 g, 6.0 mmol) and potassium carbonate (2.20 g, 16.0 mmol). The light yellow mixture was stirred for 24 h
at room temperature, where upon the mixture decolorized and H2S was released. After extraction with dichloromethane (100 mL) and washed with water (60 mL), the
organic layer was further washed with brine, dried over sodium sulfate (Na2SO4),
ﬁltered and the solvent was removed in vacuo. The crude residue was recrystallized
from nitromethane to aﬀord 0.95 g (82%) of pure compound 10 as oﬀ-white crystals
1

[21]. Yield: 82.0%; m.p: 150e153  C; [a]25
D ¼ þ488 (c 0.5, CHCl3); H-NMR (400
MHz, CDCl3): d ¼ 1.68 (d, J ¼ 11.7 Hz, 1H), 1.89e2.19 (m, 4H), 2.59e2.73 (m,
1H), 3.57e3.74 (m, 1H), 3.76e3.86 (m, 1H), 4.33 (dd, J ¼ 7.5, 2.0 Hz, 1H), 6.90 (d,
J ¼ 7.3 Hz, 1H), 7.09e7.18 (m, 1H), 7.39e7.46 (m, 1H), 7.76 (s, 1H), 7.93 (dd, J ¼
7.9, 1.6 Hz, 1H); 13C-NMR (100 MHz, CDCl3): d ¼ 23.2 (C-2), 25.9 (C-1), 47.4 (C3), 54.4 (C-11a), 120.5, 123.5, 125.8, 131.6, 132.6, 136.9, 151.2, 166.2 (CO); IR
(KBr): 3788, 3716, 3281, 2965, 2911, 2878, 2806, 2351, 1724, 1689, 1658, 1612,
1573, 1552, 1530, 1480, 1453, 1425, 1396, 1273, 1227, 1201, 1162, 1108, 1040,
997, 957, 933, 884, 847, 807, 787, 756, 701, 663; GC-MS (70 eV) m/z (%): 231
(20) [Mþ], 144 (37), 90 (35), 70 (100); HRMS m/z calcd for C12H14N3O2
[MþH]þ 232.1086, found 232.1095.
(S)-11,12,13,13a-tetrahydro-3H,9H-benzo[e][1,2,4]oxadiazolo [3,4-c]pyrrolo[1,2a][1,4]diazepine-3,9-dione (11). To a solution of compound 10 (231 mg, 1 mmol) in
anhydrous dioxane (8 mL) was added 1,10 -carbonyldiimidazole (486.45 mg, 3.3
mmol) under nitrogen. The reaction mixture was reﬂuxed for 12 h and the solvent
removed in vacuo afterward. The residue was taken up in dichloromethane and
washed three times with water. The organic layer was dried over Na2SO4 and the
solvent removed in vacuo. The crude residue was puriﬁed by ﬂash column chromatography to obtain a white solid which was recrystallized to aﬀord compound 11 as

crystals [21]. Yield: 226.16 mg (88 %); m.p.: 180e182  C; [a]25
D ¼ þ142 (c ¼ 0.5,
CDCl3); 1H-NMR (400 MHz, CDCl3): d ¼ 1.58 (d, J ¼ 12.1 Hz, 1H), 2.10e2.23

(m, 2H), 2.30e2.39 (m, 1H), 3.67e3.74 (m, 1H), 3.90e3.95 (m, 1H), 4.58e4.61
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(dd, J ¼ 8.4, 2.9 Hz, 1H), 7.49e7.53 (m, 1H), 7.64e7.68 (td, J ¼ 7.8, 1.6 Hz, 1H),
7.83e7.85 (d, J ¼ 7.3 Hz, 1H), 8.02e8.04 (dd, J ¼ 7.9, 1.6 Hz, 1H); 13C-NMR (100
MHz, CDCl3): d ¼ 23.4, 25.6, 47.9, 51.2, 122.4, 128.5, 128.6, 128.7, 132.8, 156.3
~ (cm1) ¼ 3623, 3335, 3044, 2956, 2918,
(CN), 158.0 (CO), 164.2 (CO); IR (KBr) n
2875, 2851, 2381, 2349, 2296, 2199, 2105, 1981, 1838, 1787, 1728, 1710, 1690,
1657, 1640, 1599, 1551, 1468, 1451, 1410, 1301, 1267, 1167, 1081, 1025, 990,
761, 702, 662, 608; UV lmax (MeOH): 198, 274 nm; GC-MS (70 eV) m/z (%):
257 (22) [Mþ], 144 (100), 116 (38), 90 (33), 44 (33), 41 (24); HRMS m/z calcd
for C13H12N3O3 [MþH]þ 258.0879, found 258.0871.
(S)-3-thioxo-11,12,13,13a-tetrahydro-3H,9H-benzo[e][1,2,4]

oxadiazolo[3,4-c]

pyrrolo[1,2-a][1,4]diazepin-9-one (12). To a solution of compound 10 (231 mg,
1 mmol) in anhydrous dioxane (8 mL) was added 1,10 -thiocarbonyldiimidazole
(486 mg, 3.3 mmol) under nitrogen. The reaction mixture was reﬂuxed for 12 h
and the solvent removed in vacuo afterward. The residue was taken up in dichloromethane and washed three times with water. The organic layer was dried over
Na2SO4 and the solvent removed in vacuo. The crude residue was puriﬁed by ﬂash
column chromatography to obtain a pale yellow solid and further recrystallized using
hexane: ethyl acetate (1:1 v/v) to aﬀord compound 12 as yellow crystals. Yield:
1

245.7 mg (90 %); m.p.: 216e218  C; [a]25
D ¼ þ34 (c ¼ 0.5, CDCl3); H-NMR
(400 MHz, CDCl3): d ¼ 1.17e1.27 (m, 1H), 2.06e2.29 (m, 2H), 2.32e2.47 (m,

1H), 3.65e3.72 (m, 1H), 3.90e3.95 (m, 1H), 4.57e4.60 (dd, J ¼ 8.6, 2.7 Hz,
1H), 7.55e7.59 (td, J ¼ 7.6, 0.9 Hz, 1H), 7.67e7.72 (m, 1H), 8.01e8.04 (dd,
J ¼ 8.1, 1.5 Hz, 1H), 8.27e8.29 (dd, J ¼ 8.2, 0.9 Hz, 1H); 13C-NMR (100 MHz,
CDCl3): d ¼ 23.5, 26.5, 47.6, 51.0, 124.7, 129.6, 129.7, 131.8, 132.2, 159.1
~ (cm1) ¼ 3788, 3716, 3281, 2965,
(CN), 164.5 (CO), 164.8 (CS); IR (KBr) n
2911, 2878, 2806, 2351, 1724, 1689, 1658, 1612, 1573, 1552, 1530, 1480, 1453,
1425, 1396, 1273, 1227, 1201, 1162, 1108, 1040, 997, 957, 933, 884, 847, 807,
787, 756, 701, 663; UV lmax (MeOH): 198, 276 nm; GC-MS (70 eV) m/z (%):
273 (70) [Mþ], 146 (42), 102 (75), 90 (65), 69 (44), 43 (100); HRMS m/z calcd
for C13H12N3O2S [MþH]þ 274.0650, found 274.0645.
5,6-Dihydro-4H-3-thia-6a,11b-diazabenzo[g]cyclopenta [e]azulene-1,7-dione (13).
To a solution of compound 2 (0.464 g, 2.0 mmol) in anhydrous THF (40 mL) was
added freshly distilled a-bromoacetyl chloride (0.39 g, 2.4 mmol). The mixture was
stirred for 15 h at room temperature under nitrogen and then quenched by addition
of saturated sodium bicarbonate (NaHCO3) (20 mL). After extraction with chloroform
(2  20 mL), the combined organic layers were dried over Na2SO4, and the solvent was
removed under reduced pressure. The crude residue was subjected to ﬂash silica gel
column chromatography using EtOAc/Hexane (4:1 v/v) as eluent and the solvent
was evaporated under reduced pressure to give crude yellow solids [9]. The crude solid
was puriﬁed by recrystallization from Ethanol/Water mixture to aﬀord 0.20 g (75%) of
pure compound 13 as yellow needle-like crystals. Yield: 75.0%; m.p: 165e167  C; 1H-
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NMR (400 MHz, CDCl3): d ¼ 1.98e2.05 (m, 2H), 2.67 (t, J ¼ 8.0 Hz, 2H), 3.83 (s,
2H), 3.90e3.94 (m, 2H), 7.28e7.32 (m, 1H), 7.44 (dd, J ¼ 8.2, 1.0 Hz, 1H),
7.51e7.55 (m, 1H), 8.00 (dd, J ¼ 8.0, 1.6 Hz, 1H); 13C-NMR (100 MHz, CDCl3):
d ¼ 20.8 (C-5), 31.1 (C-4), 35.8 (C-2), 50.1 (C-6), 115.5, 124.3, 124.9, 127.2,
~ (cm1) ¼ 3398,
128.5, 133.3, 133.6, 138.9, 165.4 (CO), 172.7 (CO); IR (KBr) n
3357, 3282, 2944, 2880, 2790, 2419, 2385, 2350, 2323, 1856, 1818, 1779, 1724,
1690, 1582, 1482, 1404, 1384, 1358, 1334, 1217, 1126, 1092, 871, 835, 776, 708,
659, 636; HRMS m/z calcd for C14H13N2O2S [MþH]þ 273.0698, found 273.0706.

5.1. NCI 60 Human Tumor Cell Lines Screen
NCI-60 Human Tumor Cell Lines Screen is a part of the National Cancer Institute’s
(NCI) Development Therapeutics Program (DTP)-Drug Synthesis and Chemistry
Branch. The screening utilizes 60 diﬀerent human tumor cell lines to identify and
characterize novel compounds with growth inhibition or cell death. The 60 human
tumor cell lines represent leukemia, melanoma, and cancers of the lung, colon, brain,
ovary, breast, prostate, and kidneys. The NCI-60 screening is free of cost to those
who submit compounds; however, compounds submitted are reviewed and only
those that meet the guidelines set by the NCI are selected for screening. Compounds
that selected for the NCI-60 cell screening are initially dissolved in DMSO:glycerol
9:1 and tested at a single concentration of 10 mM. The One-dose data is reported in
graphical form as a mean of the percent growth of treated cells (Fig. 3). The value
reported for the One-dose assay of the individual compounds is cell growth relative
to the no-drug control in addition to the initial number of tumor cells present, which
allows for the detection of both growth inhibition (values between 0 and 100) and
tumor cell death (values less than 0). Compounds that satisfy predetermined thresholds for the One-dose assay set by the NCI are tested by a Five-dose assay.

5.2. Cell culture maintenance
The cells lines that originated in multiple tissue types were obtained from the American Tissue Type Culture Collection (ATCC), including: breast (SK-BR-3, MCF-7),
colon (Caco-2, HCT 116), melanoma (SKMEL-2), and pancreatic (Mia Paca) cell
lines. The tumor cell lines were grown in their respective medium according to
ATCC instructions. Each medium was supplemented with 10% serum and penicillin/streptomycin. Cell lines were allowed to reach 75% conﬂuency before treatment with the novel pyrrolobenzodiazepines or negative control (DMSO at a ﬁnal
maximum concentration of 0.01%). The cell lines obtained from the ATCC were
stored in liquid nitrogen until ready to use. Once the compounds were synthesized
and ready to be tested, each cell line was allowed to thaw at room temperature,
respectively. They were then transferred to a centrifuge tube, diluted by 5 mL of their
respective media (listed on the ATTC website), and centrifuged for 3 minutes. The
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supernatant ﬂuid was then removed, and the pellet was re-suspended in 10 mL of its
media, and mixed thoroughly using a pipette. Finally, the solution was transferred to
a 25-cm2 vented ﬂask, and placed in an incubator. The incubator maintained an atmosphere of 37  C and 5% carbon dioxide. The media inside the culture ﬂask was
exchanged with fresh media every few days in order to remove dead cells and provide fresh nutrients. The cells were allowed to grow until they reached 75% conﬂuency. Once cells were 75% conﬂuent, the media was removed from the ﬂask and 1.5
mL of trypsin was added in order to lift the cells from the ﬂask. The solution of cells
were then transferred to a centrifuge tube, and diluted with 5 mL of media. Again,
the solution was centrifuged for 3 minutes until all of the cells formed a pellet in the
bottom of the tube. The supernatant ﬂuid was then removed and replaced with 10 mL
of media, and the pellet was mixed well into solution.

5.3. MTT assay
The ﬁrst method used to test the in vitro cytotoxicity of our compounds was the MTT
Assay. For our tests, we used 48-well plates. 1 mL of each cell line’s respective media was placed into each well of the 48-well plates, and 1 drop of the ﬁnal solution of
the cells listed in the previous section were be added to each well and allowed to
grow to 75 % conﬂuency (covering 75% of the bottom of the well). Next, our products were added to the wells at a concentration of 100 mM, except for four wells in
which DMSO was added so that the ﬁnal concentration was 0.01% (negative control). Once the PBD products were added in triplicate, the plates were incubated
for 48 hours. After 48 hours of incubation, 5-diphenyl-tetrazolium bromide
(MTT) was added at 100 mg/well and will be incubated for 3e4 hours. After 3e4
hours of incubation, the supernatant ﬂuid was removed and 0.1 M HCl in isopropanol was added to each well to dissolve the resulting formazan crystals. The crystals
were dissolved into solution well using a transfer pipette. The optical density of the
resulting solution was measured at 570 nm. The optical density of the solution of the
formazan crystals is directly correlated to the remaining number of viable cells in
solution. Percent cell viability was calculated by comparing the concentration of formazan crystals formed in the negative control to the formazan crystals formed by the
sample in which our PBD products are added. The cell viability of the negative controls were taken to be 100%.
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